Canadian Glycomics Network – Improving the quality of life of Canadians through glycomics

GlycoNet Integrated Services, a pan-Canadian glycomics facility, is one of the world’s leading glycomics facility to accelerate the discovery, development and commercialization of next-generation, sustainable, one-health innovations. The fully integrated national platform include 7 sites across Canada offering the following glycomics services:

– Glycan–Ligand Screening and Discovery
– Glycan Analysis
– Carbohydrate Synthesis
– Drug Discovery & High-Throughput Screening (HTS)
– Molecular Glycobiology & Glycoengineering

Our services, instruments, technologies and professional services are available to all researchers, from Canada and abroad, across academic, private, and government sectors. The facility’s scientific and technical personnel provides high-quality, high-throughput, and competitively priced products and services to all of its clients.

GlycoNet Integrated Services are funded by the Government of Canada through the Canada Foundation for Innovation – Major Science Initiatives Fund.

GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians.

GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs. The network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.

GlycoNet is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

Why is glycomics important?

In 2020, 5 of the top 10 selling drugs are glycosylated and have a combined revenue of US$58B.
Global market for glycomics drugs to reach US$257B by 2028.